OXB Highlights the Launch of its Innovation and Technology Excellence Board

Core Insights - OXB has launched the Innovation and Technology Excellence Board (ITEB) to enhance its capabilities in cell and gene therapy and maintain its leadership position in the market [1][2][3] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver transformative therapies to patients [15][16] - The company has 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies [16] Strategic Initiatives - The ITEB will provide strategic insights to identify opportunities for scientific enhancement and innovation, ensuring OXB remains at the forefront of technology development [2][3] - The board aims to improve treatment development, manufacturing, and delivery processes, focusing on practical advances for clients and better patient outcomes [3] Leadership and Expertise - The ITEB is chaired by Prof. Dame Kay Davies, a respected figure in human genetics, with founding members including leading experts in molecular biology, gene therapy, and biopharmaceuticals [3][4][5][6][7] - Dr. Frank Mathias, CEO of OXB, emphasizes the importance of the ITEB in adapting to scientific and technological changes to better serve clients [3][10] Technological Capabilities - OXB offers unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system and advanced AAV production methods [17] - The company supports its capabilities with robust quality-assurance systems and regulatory expertise, facilitating a range of services from early-stage development to commercialization [16]